nivolumab


( Last Updated : September 27, 2022)
Generic Name:
nivolumab
Project Status:
Active
Therapeutic Area:
Resectable Non-Small Cell Lung Cancer
Manufacturer:
Bristol-Myers Squibb
Call for patient/clinician input open:
Brand Name:
Opdivo
Project Line:
Reimbursement Review
Project Number:
PC0303-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
​Neoadjuvant treatment of adult patients with resectable NSCLC (tumours ≥4cm or node positive) when used in combination with platinum-doublet chemotherapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Neoadjuvant treatment of adult patients with resectable NSCLC (tumours ≥4cm or node positive) when used in combination with platinum-doublet chemotherapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open15-Aug-22
Call for patient/clinician input closed07-Oct-22
Submission received13-Sep-22
Submission accepted27-Sep-22
Review initiated28-Sep-22
Draft CADTH review report(s) provided to sponsor for comment12-Dec-22
Deadline for sponsors comments21-Dec-22
CADTH review report(s) and responses to comments provided to sponsor27-Jan-23
Expert committee meeting (initial)08-Feb-23
Draft recommendation issued to sponsorFebruary 21, 2023
To
February 23, 2023
Draft recommendation posted for stakeholder feedback02-Mar-23
End of feedback period16-Mar-23